MoonLake Immunotherapeutics

MLTX

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001821586

SEC filings (opens in a new tab)

In the last 90 days, MoonLake Immunotherapeutics insiders filed 0 open-market purchases and 5 sales; 172 institutions reported holding it in 13F filings for Q2 2026, worth $1.43B in total; no superinvestor holds it.

Q2 2025 vs. Q1 2025

How the institutions holding MoonLake Immunotherapeutics changed between Q1 2025 and Q2 2025.

All holders in Q2 2025 All holders in Q1 2025

13F holders of MLTX: Q1 2025 compared with Q2 2025
Measure	Q1 2025	Of which not filed for Q2 2025	Q2 2025	Change
Holders	136	2	130	−4
Shares	59.9M	6.69K	58.8M	−1.12M (−1.9%)
Value	$2.34B	$261.5K	$2.77B	+$434.1M (+18.6%)

2 institutions that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so the changes leave them out.

New holders (23)

Institutions that held MoonLake Immunotherapeutics at the end of Q2 2025 but not at the end of Q1 2025.

Institutions new to MLTX in Q2 2025
Institution	Shares	Value	% of portfolio
RTW Investments, LP	741,090	$35.0M	0.50%
Siren, L.L.C.	508,267	$24.0M	1.24%
Point72 Asset Management, L.P.	186,568	$8.81M	0.02%
Silverarc Capital Management, LLC	82,023	$3.87M	0.79%
Jennison Associates LLC	62,318	$2.94M	0.00%
Avidity Partners Management LP	39,000	$1.84M	0.37%
ExodusPoint Capital Management, LP	25,313	$1.20M	0.01%
Schroder Investment Management Group	19,390	$915.2K	0.00%
Winton Group Ltd	12,565	$593.1K	0.03%
Glenmede Investment Management, LP	6,635	$313.2K	0.00%
Caption Management, LLC	5,969	$281.7K	0.03%
Mount Yale Investment Advisors, LLC	1,565	$73.9K	0.01%
T. Rowe Price Investment Management, Inc.	509	$25.0K	0.00%
Clearstead Advisors, LLC	490	$23.1K	0.00%
BNP PARIBAS ASSET MANAGEMENT Holding S.A.	257	$12.0K	0.00%
Skopos Labs, Inc.	110	$5.19K	0.00%
Bessemer Group Inc	100	$5.00K	0.00%
Allworth Financial LP	50	$2.36K	0.00%
Quantbot Technologies LP	49	$2.31K	0.00%
Riggs Asset Managment Co. Inc.	24	$1.13K	0.00%
IFP Advisors, Inc	17	$802	0.00%
Signaturefd, LLC	11	$519	0.00%
Principal Securities, Inc.	8	$378	0.00%

Sold out (27)

Institutions that held MoonLake Immunotherapeutics at the end of Q1 2025 and filed for Q2 2025 without it.

Institutions that sold out of MLTX in Q2 2025
Institution	Shares, Q1 2025	Value, Q1 2025
Camber Capital Management LP	441,000	$17.2M
Finepoint Capital LP	435,785	$17.0M
Millennium Management LLC	344,320	$13.5M
Franklin Resources Inc	191,500	$7.48M
Holocene Advisors, LP	188,989	$7.38M
First Turn Management, LLC	179,196	$7.00M
Nicholas Investment Partners, LP	46,933	$1.83M
Two Sigma Investments, LP	35,638	$1.39M
Jane Street Group, LLC	27,489	$1.07M
Walleye Capital LLC	26,764	$1.05M
Two Sigma Advisers, LP	25,400	$992.4K
Cantor Fitzgerald, L. P.	25,000	$976.8K
Wexford Capital LP	21,500	$840.0K
J. Goldman & Co LP	14,664	$572.9K
BIT Capital GmbH	14,610	$570.8K
Schonfeld Strategic Advisors LLC	10,669	$416.8K
Allianz Asset Management GmbH	9,900	$386.8K
Dark Forest Capital Management LP	9,510	$371.6K
Caxton Associates LLP	8,880	$346.9K
XTX Topco Ltd	8,495	$331.9K
New York State Common Retirement Fund	6,992	$273.2K
Legato Capital Management LLC	6,142	$240.0K
Wealth Preservation Advisors, LLC	120	$4.69K
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A.	85	$3.32K
Amundi	12	$457
Creative Financial Designs Inc	10	$391
TD Private Client Wealth LLC	9	$352

Not filed for Q2 2025 yet (2)

Institutions that held MoonLake Immunotherapeutics at the end of Q1 2025 and haven't filed a 13F for Q2 2025. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding MLTX in Q1 2025 that haven't filed for Q2 2025
Institution	Shares, Q1 2025	Value, Q1 2025
Glenmede Trust Co NA	6,690	$261.4K
Lindbrook Capital, LLC	4	$156